No Data
Guo Guangchang: Fosun Emphasizes Strategic Advancement and Exits, Focuses on Core Businesses, and Leverages Operational Capabilities to Participate in Global Markets
Hong Kong stock movements | HENLIUS (02696) rose over 4% in the afternoon, Hanbetai received approval for listing in Bolivia, the company is accelerating the expansion of its overseas market.
HENLIUS (02696) rose over 4% in the afternoon; as of the time of publication, it has increased by 4.33%, priced at HKD 22.9, with a transaction amount of HKD 38.2759 million.
Express News | UBS Group's Long Position in H Shares of Shanghai Henlius Biotech Increases to 7.55% on Feb 13 From 5.43% - HKEX
Trending Industry Today: WUXI BIO Leads Gains In Biotechnology Stocks
FDA Approves Shanghai Henlius Biotech's Investigational New Drug Application for Anti-Neurodegenerative Disease Drug
FOSUN PHARMA (02196.HK): HENLIUS plans to conduct the Phase I clinical trial of HLX99 in the USA when conditions permit.
On February 10, Gelonghui reported that FOSUN PHARMA (02196.HK) announced that its holding subsidiary, Shanghai HENLIUS Biotechnology Co., Ltd and its holding subsidiaries (hereinafter collectively referred to as "HENLIUS") recently received approval from the USA FDA (i.e., the United States Food and Drug Administration) to initiate clinical trials for HLX99. HENLIUS plans to conduct Phase I clinical trials for HLX99 in the USA once conditions are met. HLX99 is an innovative small-molecule conjugated chemical drug independently developed by the group, intended for the treatment of Amyotrophic Lateral Sclerosis (ALS). As of December 2024, the group currently
